Prena

Prena is a private, pre-revenue biotech company targeting the significant unmet need of preterm birth prevention. Its novel approach leverages photo biomodulation via a cerulean blue light sleep mask to downregulate melatonin, a hormone linked to the initiation of labor. The company has completed proof-of-concept human studies showing over 70% efficacy in stopping or reducing contractions, has a product that is 95% complete, and is now advancing plans for pivotal trials in the US and UK with a team of seasoned executives and renowned clinical advisors.

Non-invasive photo biomodulation using cerulean blue light delivered via a sleep mask to downregulate nocturnal melatonin secretion, thereby inhibiting melatonin-mediated uterine contractions associated with preterm labor.

The current standard of care (tocolytics) is limited by efficacy and side effects, creating a near-open field. Competition may come from other biotech/pharma companies investigating alternative pharmacological targets for preterm labor, but Prena's non-invasive, device-based approach appears unique. Its main competition is the status quo of inadequate treatment options.